EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dapagliflozin mitigates myocardial inflammation and metabolic stress in heart failure through STAT1 inhibition: Evidence from multi-omics analyses and experimental exploration

Dapagliflozin mildert Myokardentzündung und metabolischen Stress bei Herzinsuffizienz durch STAT1-Hemmung: Evidenz aus Multi-omics-Analysen und experimenteller Untersuchung

Lianqi He, Di Zhang, Shiwen Zhang, Zhichao Ren, Yihong Huangfu, Xiran Cheng, Zhanchun Song iD

PLOS One · 27.02.2026 · 21 (2) · e0343296

DOI: 10.1371/journal.pone.0343296 ↗

Auf einen Blick

Multi-omics-Analysen und Experimente deuten darauf hin, dass Dapagliflozin bei Herzinsuffizienz Entzündung und metabolischen Stress über STAT1 hemmt. Im Tiermodell und in Zellen waren STAT1 und entzündliche Veränderungen unter Dapagliflozin abgeschwächt.

Fragestellung

Welche Rolle spielt STAT1 bei Herzinsuffizienz, und wie beeinflusst Dapagliflozin STAT1-abhängige Veränderungen?

Methode

Bulk- und Single-Cell-Transkriptomik mit experimenteller Validierung; Daten aus GSE57345 und GSE145154 sowie Rattenmodell und H9C2-Zellen.

Ergebnisse

In HF zeigten sich Aktivierungen von Gallen­säure-, Aminosäure- und Lipoinsäure-Stoffwechselwegen sowie eine Immunumstellung mit mehr M1- und weniger M2-Makrophagen. Dapagliflozin senkte STAT1, Entzündung und Apoptose und verbesserte die Zellviabilität.

Schlussfolgerung der Autor:innen

STAT1 ist ein zentraler Vermittler zwischen metabolischen Störungen und Immun-Dysregulation bei HF. Dapagliflozin lindert HF durch Hemmung von STAT1-Signalen und Wiederherstellung des immunmetabolischen Gleichgewichts.

Kernaussagen

  • STAT1 war bei HF mit metabolischem Stress und Immunimbalance verknüpft.
  • Dapagliflozin senkte STAT1 und entzündliche Marker im Tiermodell.
  • In H9C2-Zellen verbesserte Dapagliflozin die Viabilität und senkte Apoptose.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 27.02.2026. Verfasst von Lianqi He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Central Hospital of Fushun, Fushun, Liaoning, China. Hauptthemen laut MEDLINE: STAT1 Transcription Factor, Heart Failure, Glucosides, Benzhydryl Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the talent Program of Fushun City of China.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure (HF) is a global health challenge with high morbidity and mortality. While dapagliflozin (DAPA), a sodium–glucose cotransporter 2 inhibitor, has proven clinical benefits in HF, its molecular mechanisms remain unclear.

Methods

We integrated bulk and single-cell transcriptomic analyses with experimental validation to investigate the role of STAT1 in HF and its modulation by DAPA. Bulk RNA sequencing data from the GSE57345 dataset were analyzed for differential expression, enrichment, and weighted gene co-expression network analysis (WGCNA) to identify hub regulators. Single-cell RNA sequencing data (GSE145154) included normal controls (n = 4), dilated cardiomyopathy (DCM, n = 8), ischemic cardiomyopathy infarct regions (ICM_MI, n = 6), and non-infarct regions (ICM_NMI, n = 6), and were processed with Seurat and Harmony for integration, clustering, myeloid subcluster profiling, and AUCell pathway scoring. For in vivo validation, a rat model of myocardial infarction–induced HF was established and divided into control, HF, and HF+DAPA groups (6 mg/kg/day for 4 weeks). Histological examination, Western blotting, ELISA, flow cytometry, and serum bile acid assays were conducted. For in vitro assays, STAT1-overexpressing H9C2 cardiomyocytes were generated by lentiviral transduction. Cell viability (CCK‑8), STAT1 expression (qPCR and Western blot), and apoptosis (Annexin V/PI flow cytometry) were assessed with or without DAPA treatment.

Results

Transcriptomic analyses revealed widespread activation of bile acid, amino acid, and lipoic acid metabolic pathways in HF, coupled with immune remodeling dominated by increased M1 and reduced M2 macrophages. STAT1 emerged as a central hub gene linking metabolic stress and immune imbalance. Single-cell analysis confirmed aberrant STAT1 expression particularly in M1 and proliferating myeloid clusters. In vivo, DAPA suppressed myocardial STAT1 expression, alleviated inflammation, normalized macrophage polarization, and reduced cytokine and bile acid abnormalities. In vitro, DAPA rescued STAT1-overexpressing cardiomyocytes by restoring viability and reducing apoptosis.

Conclusions

STAT1 acts as a pivotal mediator bridging metabolic disturbances and immune dysregulation in HF. DAPA alleviates HF by inhibiting STAT1 signaling, thereby restoring immunometabolic balance and protecting cardiac tissue. These findings provide mechanistic insight into the cardioprotective effects of DAPA and position STAT1 as a promising biomarker and potential therapeutic candidate for HF management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT1 Transcription FactorHeart FailureGlucosidesBenzhydryl CompoundsStress, PhysiologicalAnimalsRatsMaleInflammationMultiomicsMyocardiumRats, Sprague-DawleyHumansMyocytes, CardiacApoptosisMyocardial InfarctionGene Expression Profiling

Substanzen

STAT1 Transcription FactorGlucosidesdapagliflozinBenzhydryl CompoundsStat1 protein, rat

Autor:innen und Institutionen

  • Department of Cardiology, Central Hospital of Fushun, Fushun, Liaoning, China.
  • Graduate School, Jinzhou Medical University, Jinzhou, Liaoning, China.
  • Changsha Medical College, Changsha, Hunan, China.

ORCID-Profile: Zhanchun Song

Förderung

  • the talent Program of Fushun City of China

Zitieren

APA

He, L., Zhang, D., Zhang, S., Ren, Z., Huangfu, Y., Cheng, X., & Song, Z. (2026). Dapagliflozin mitigates myocardial inflammation and metabolic stress in heart failure through STAT1 inhibition: Evidence from multi-omics analyses and experimental exploration. PLOS One, 21(2), e0343296. https://doi.org/10.1371/journal.pone.0343296

Vancouver

He L, Zhang D, Zhang S, Ren Z, Huangfu Y, Cheng X, et al. Dapagliflozin mitigates myocardial inflammation and metabolic stress in heart failure through STAT1 inhibition: Evidence from multi-omics analyses and experimental exploration. PLOS One. 2026;21(2):e0343296. doi:10.1371/journal.pone.0343296

BibTeX
@article{He2026,
  author = {He, Lianqi and Zhang, Di and Zhang, Shiwen and Ren, Zhichao and Huangfu, Yihong and Cheng, Xiran and Song, Zhanchun},
  title = {Dapagliflozin mitigates myocardial inflammation and metabolic stress in heart failure through STAT1 inhibition: Evidence from multi-omics analyses and experimental exploration},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {2},
  pages = {e0343296},
  doi = {10.1371/journal.pone.0343296}
}
Kostenlos starten →